The mode of action of the known antifungal macrolides rustmicin (1) and galbonolide B (2) has been determined to be the inhibition of sphingolipid biosynthesis. A large scale fermentation and isolation process was developed for production of large quantities of rustmicin. New 21-hydroxy derivatives of both compounds were isolated from pilot scale fermentations and were also produced by biotransformation of rustmicin and galbonolide B.
Natural products are a rich source of sphingolipid biosynthesis inhibitors. The sphingofungins1,2), lipoxamycin3), myriocin4) and viridiofungins5,6) inhibit serine palmitoyltransferase, the first committed enzyme of sphingolipid synthesis. Fumonisin Bl7) and australifungin8,9) inhibit sphinganine N-acyltransferase (ceramide synthase). All of these natural products have antifungal activity. These early steps of sphingolipid synthesis have mammalian counterparts and thus are less attractive as targets for antifungal therapy. The first fungal-specific enzyme in sphingolipid biosynthesis is inositol phosphoceramide (IPC) synthase. It catalyzes the transfer of phosphoinositol from glycerophosphatidylinositol to the C1 hydroxyl of ceramide to produce inositol phosphoceramide which is further elaborated in fungi. We have targeted the fungal specific steps of sphingolipid synthesis in our natural product screening program with the goal of obtaining a broad spectrum, fungicidal agent without mammalian toxicity. In this report we demonstrate that the known antifungal macrolides rustmicin (1) and galbonolide B (2) inhibit fungal sphingolipid biosynthesis. Their new 21-hydroxy derivatives are also described.
Experimental
General Methods unless otherwise noted, at either 100/400 or 125/500MHz on a Varian Unity spectrometer equipped with a Nalorac inverse detection microprobe. Chemical shifts are reported downfield from TMS and spectra were referenced to the solvent peak. UV spectra were recorded on a Beckman model DU70 spectrophotometer. IR spectra were recorded as a thin film on a ZnSe multiple internal reflectance crystal using a Perkin Elmer model 1750 spectrophotometer. MS were recorded on a JEOL SX-102A (electron impact, EI, 90eV) mass spectrometer. Exact mass measurements were performed at high resolution (HR-EI) using perfluorokerosene (PFK) as an internal standard. Optical rotations were measured on a Perkin Elmer model 241 polarimeter. Methanol extracts of Micromonospora sp. culture MA 7094 were found to inhibit sphingolipid biosynthesis and exhibited potent antifungal activity, especially against Cryptococcus neoformans and non-albicans Candida species. A survey of a portion of this extract using gradient RP HPLC revealed one major antifungal zone, and several, slightly more polar minor zones. The major antifungal zone was confirmed to inhibit sphingolipid biosynthesis. To identify the compound responsible for this activity, the methanol extract was concentrated in vacuo to remove the methanol and the remaining aqueous layer was extracted with CH2Cl2. Two active components corresponding to the major activity zone were purified from the CH2Cl2 layer using silica gel column chromatography and preparative reverse phase RP HPLC.
The most potent of the two compounds was identified as the antifungal macrolide rustmicin (galbonolide A), 1. 1H/13C NMR, MS, UV spectral data and optical rotation for this isolate were identical to that reported for both rustmicin12) and galbonolide A13). Spectral data for the second component was identical to that reported for galbonolide B, 2. The structure for this isolate of 2 was confirmed from extensive NMR (COSY, HMQC and HMBC) and X-ray crystallographic data. 13C NMR data (Table 1) for this isolate are consistent with that reported for galbonolide B13), but not with that reported for neorustmicin A14). The structure proposed for neorustmicin A by ABE, et al. is identical to that of galbonolide B. However it has been suggested that neorustmicin A is incorrect and more likely analogous to a minor galbonolide15). The data on this isolate of 2 support this suggestion. The absolute stereochemistry of both 1 and 2 were later determined by total synthesis16,17). Numerous minor components related to 1 and 2 were produced by both MA 7094 and mutant MA 7186. Only those more polar than 1, as judged by RP HPLC and silica gel elution, inhibited sphingolipid biosynthesis and had antifungal activity. The two most abundant of these were isolated from the large scale SP207 rich cut described above using silica gel chromatography followed by preparative RP HPLC. The structure of the first minor component, 21-hydroxyrustmicin (3), was determined from analysis of NMR (1H, 13C, COSY, HMQC and HMBC) and MS Figure 3 and complete NMR assignments are summarized in Table 2 . 3 produced by MA 7186 was identical to 3 produced by biotransformation of 1 establishing the absolute stereochemistry of the natural product.
The structure of the second minor component, 21-hydroxygalbonolide B (4), was similarly determined. In contrast to 3, a molecular ion was observed in the HREI-MS of 4 (found 380.2187, calc 380.2199) cor- responding to the molecular formula of C21H32O6.
Fragmentation of between C-8 and C-9 yielded the same 137m/z ion for the C-9 to C-15 hydroxylated portion of the molecule that was observed in the HREI-MS of 3 ( Figure 2 ). The NMR data for the left side of 4 was very similar to that of 3 ( Table 2 ). 4 produced by MA 7186 was identical to 4 produced by biotransformation of 2 establishing the absolute stereochemistry of the natural product.
Biotransformation of 1 and 2
Random screening of Streptomyces sp. cultures for the ability to biotransform 1 and 2 yielded a culture (MA THE JOURNAL OF ANTIBIOTICS SEPT. 1998 Table 2 . 1H and 13C NMR assignments for 3 and 4 in C6D6.
7165) capable of converting both compounds to a more polar product. The polarity of the products suggested that the biotransformation might involve hydroxylation. Small quantities of each were isolated and characterized. Molecular ions 16 mass units higher than the starting compound were observed in the MS of both products consistent with hydroxylation. The site of hydroxylation was determined to be C-21 from analysis of 1H NMR and MS data and comparison of the natural products produced by culture MA 7186 with the biotransformation derived compounds showed them to be identical. Epimerization of the C-2 methyl group under biotransformation conditions is unlikely and therefore the stereochemistry of 3 and 4 should be identical to that of 1 and 2 respectively. Compounds 1 and 2 were first isolated for their growth inhibitory activity against plant pathogenic fungi19,20). Investigation into their mode of action indicated that they did not destabilize membranes, or inhibit the synthesis of chitin, DNA or RNA, but the mechanism of their antifungal activity was not determined. In the course of screening for fungal specific inhibitors of sphingolipid synthesis, we isolated 1 and 2. The effects of 1 and 2, and related minor components 3 and 4, on 3H -inositol incorporation into the deacylation-resistant sphingolipids of C. albicans and C. neoformans are shown in Figure 4 . None of the compounds affected phosphatidylinositol synthesis, but all of them inhibited sphingolipid synthesis with varying levels of potency. 1 was the most potent compound with an approximate IC50 of THE JOURNAL OF ANTIBIOTICS 843 15ng/ml for inhibition of inositol incorporation in the sphingolipids of C. albicans ( Figure 4A ). Compounds 2 and 3 were 60-fold less potent, and 4 was over 1000-fold less active than 1 at inhibiting sphingolipid synthesis in C. albicans. When the compounds were tested against C. neoformans, they demonstrated the same rank order of activity, but were considerably more potent at inhibiting sphingolipid synthesis in this pathogen ( Figure  4B ). C. neoformans was remarkably sensitive to 1, with an approximate IC50 of 0.15ng/ml. Analysis of in vitro enzyme activities and the accumulation of sphingolipid intermediates resulted in the identification of the inositol phospoceramide synthase as the target enzyme in the sphingolipid biosynthetic pathway for these inhibitors21).
Antifungal Activity
Antifungal activity of the macrolides against clinically relevant human pathogens was measured in a microbroth dilution assay (Table 3 ). Similar to previous results, compound 1 had moderate antifungal activity against C. albicans and was inactive against A. fumigatus (Table   3) 12,15). Additionally, we found that 1 was very active at inhibiting the growth of several non-albicans Candida species including C. tropicalis, and was extremely potent against C. neoformans. The related macrolides were less active than 1 as antifungal agents and, as expected from the sphingolipid inhibition data, C. neoformans was the most sensitive organism to this class of compounds.
However, the correlation between sphingolipid inhibition and antifungal activity was limited. We have found that activity in the long term antifungal assays is influenced by a combination of factors that include in vitro potency against the enzyme, chemical stability of the macrolactone structure, and the activity of multidrug efflux pumps in the fungal pathogens21). 
